Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model

Gut

Volumn 57, Issue 4, 2008, Pages 483-491

  Maletzki, C ^a   Linnebacher, M ^a   Kreikemeyer, B ^a   Emmrich, J ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LACTATE DEHYDROGENASE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL ANTIGEN; CANCER VACCINE; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER MODEL; CANCER REGRESSION; CANCER TISSUE; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EMBRYO; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME RELEASE; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INTERFERON PRODUCTION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; DISEASE MODEL; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE; METHODOLOGY; PANCREAS TUMOR; PATHOLOGY; SPLEEN;

ANIMALS; ANTIGENS, BACTERIAL; CANCER VACCINES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; IMMUNOLOGIC MEMORY; LYMPHOCYTES; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; SPLEEN; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 41149145055     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.125419     Document Type: Article

References (39)

1. Staib L, Link KH, Beger HG. Immunotherapy in pancreatic cancer - current status and future. Langenbeck's Arch Surg 1999;384:396- 404.
2. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529-64.
3. Suzuki S, Shinohara N, Harabayashi T, et al. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 2002;7:289-93.
4. Ishii KJ, Kawakami K, Gursel I, et al. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clin Cancer Res 2003;9:6516-22.
5. Melief CJ, Toes RE, Medema JP, et al. Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-82.
6. Pastan I, Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 1998;8:E532-51.
7. Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000;7:269-74.
8. Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001;66:165-70.
9. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA 2004;101:15172-77.
10. Dang LH, Bettegowda C, Huso DL, et al. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001;18:15155-60.
11. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005;102:755-60.
12. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:197- 209.
13. Bruell D, Bruns CJ, Yezhelyev M, et al. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA′ demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 2005;15:305-13.
14. Kalady MF, Onaitis MW, Emani S, et al. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J Gastrointest Surg 2004;8:175-81.
15. Schneider C, Schmidt T, Ziske C, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004;53:355-61.
16. Tepel J, Dagvadorj O, Kapischke M, et al. Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. Int J Colorectal Dis 2006;21:365-72.
17. Cunningham M. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511.
18. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;4:717-26.
19. Klenk M, Koczan D, Guthke R, et al. Global epithelial cell transcriptional responses reveal Streptococcus pyogenes Fas regulator activity association with bacterial aggressiveness. Cell Microbiol 2005;7:1237-50.
20. Jaster R, Lichte P, Fitzner B, et al. Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells. J Cell Mol Med 2005;9:670-82.
21. Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. Cancer Gene Ther 2001;24:502-10.
22. Shan BE, Hao JS, Li QX, et al. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol 2006;3:47-52.
23. Cervi D, Klement G, Stempak D, et al. Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease. Clin Cancer Res 2005;15:712-9.
24. Quinn RW, Lowry PN. Effect of Streptococcus pyogenes on tissue cells. J Bacteriol 1967;3:1825-31.
25. Sierig G, Cywes C, Wessels MR, et al. Cytotoxic effects of streptolysin O and streptolysin S enhance the virulence of poorly encapsulated group A streptococci. Infect Immun 2003;71:446-55.
26. Marouni MJ, Sela S. Fate of Streptococcus pyogenes and epithelial cells following internalization. J Med Microbiol 2004;53:1-7.
27. Molinari G, Rohde M, Talay SR, et al. The role played by the group A streptococcal negative regulator Nra on bacterial interactions with epithelial cells. Mol Microbiol 2001;40:99-114.
28. Goldmann O, Rohde M, Chhatwal GS. Role of macrophages in host resistance to group A streptococci. Infect Immun 2004;72:2956-63.
29. Hryniewicz W, Pryjma J. Effect of streptolysin S on human and mouse T and B lymphocytes. Infect Immun 1977;16:730-3.
30. Priebe TS, Atkinson EN, Pan BF, et al. Intrinsic resistance to anticancer agents in the murine pancreatic adenocarcinoma PANCO2, Cancer Chemother Pharmacol 1992;29:485-9.
31. Schmidt T, Ziske C, Marten A, et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 2003;63:8962- 7.
32. Wilkoff LJ, Dulmadge EA. Sensitivity of proliferating cultured murine pancreatic tumor cells to selected antitumor agents. J Natl Cancer Inst 1986;77:1163-9.
33. Goldmann O, Chhatwal GS, Medina E. Contribution of natural killer cells to the pathogenesis of septic shock induced by Streptococcus pyogenes in mice. J Infect Dis 2005;191:1280-6.
34. Medina E, Goldmann O, Rohde M, et al. Genetic control of susceptibility to group A streptococcal infection in mice. J Infect Dis 2001;184:846-52.
35. Medina E, Goldmann O, Toppel AW, et al. Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion. J Infect Dis 2003;187:597-03.
36. Goldmann O, Chhatwal S, Medina E. Immune mechanisms underlying host susceptibility to infection with group A streptococci. J Infect Dis 2003;187:854-61.
37. Avogadri F, Martinoli C, Petrovska L, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 2005 1;65:3920-7.
38. Ahmed SU, Okamoto M, Oshikawa T, et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother (1997). 2004;27:432-41.
39. Ono T, Harada M, Yamada A, et al. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. Clin Cancer Res 2006 15;12:1325-32.